Quarterly report pursuant to Section 13 or 15(d)

SCHEDULE OF ACCRUED EXPENSES (Details)

v3.23.2
SCHEDULE OF ACCRUED EXPENSES (Details) - USD ($)
Jun. 30, 2023
Dec. 31, 2022
Payables and Accruals [Abstract]    
Accrued pre-clinical and clinical costs $ 2,694,611 $ 2,137,317
Accrued product development costs 758,699 247,500
Accrued compensation 1,570,376 2,224,951
Accrued administrative costs 282,846 473,376
Accrued interest 1,112,271 916,108
Total $ 6,418,803 $ 5,999,252